Jerome B. Zeldis

21.5k citations

202 papers · 15.4k indexed · 6 hit papers · h-index 59

Hematology top 0.02%
Molecular Biology top 0.5%
Oncology top 0.2%
Genetics top 0.1%
Epidemiology top 2%

Co-authors: Robert Knight Zhinuan Yu Marta Olesnyckyj David S. Siegel Bart Barlogie Elias Anaissie John Patin Raman Desikan
Topics: Multiple Myeloma Research and Treatments (103 papers)Cancer Treatment and Pharmacology (48 papers)Chronic Lymphocytic Leukemia Research (32 papers)
Cited by: Hematology Genetics Oncology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: United States Greece Canada

In The Last Decade

Jerome B. Zeldis

199 papers receiving 15.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 2.0k citations Jerome B. Zeldis et al. New England Journal of Medicine profile →
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

2007 1.1k citations Meletios Α. Dimopoulos, Andrew Spencer et al. New England Journal of Medicine profile →
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

2007 925 citations Donna M. Weber, Christine Chen et al. New England Journal of Medicine profile →
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

2006 893 citations Alan F. List, Gordon W. Dewald et al. New England Journal of Medicine profile →
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

2002 630 citations Jerome B. Zeldis et al. Blood profile →
Efficacy of Lenalidomide in Myelodysplastic Syndromes

2005 613 citations Alan F. List, Robert Knight et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Jerome B. Zeldis

Since Specialization

Citations

This map shows the geographic impact of Jerome B. Zeldis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerome B. Zeldis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerome B. Zeldis more than expected).

Fields of papers citing papers by Jerome B. Zeldis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerome B. Zeldis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerome B. Zeldis. The network helps show where Jerome B. Zeldis may publish in the future.

Co-authorship network of co-authors of Jerome B. Zeldis

This figure shows the co-authorship network connecting the top 25 collaborators of Jerome B. Zeldis. A scholar is included among the top collaborators of Jerome B. Zeldis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerome B. Zeldis. Jerome B. Zeldis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis 2018 ·ACS Medicinal Chemistry Letters ·(unknown),(unknown),(unknown),(unknown),(unknown),Ronald Goldberg,Stacie Canan,Natalie A. Hawryluk,Deborah S. Mortensen,Vikram Khetani,Jerome B. Zeldis,John J. Siekierka,David P. Rotella	4
2	Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention 2017 ·Drug Safety ·Nancy A. Brandenburg,Robert Bwire,John Freeman,Florence Houn,(unknown),Jerome B. Zeldis	29
3	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study 2016 ·Journal of Clinical Oncology ·Mark N. Polizzotto,Thomas S. Uldrick,Kathleen M. Wyvill,Karen Aleman,Cody J. Peer,Margaret Bevans,Irini Sereti,Frank Maldarelli,Denise Whitby,Vickie Marshall,Priscila Gonçalves,Vikram Khetani,William D. Figg,Seth M. Steinberg,Jerome B. Zeldis,Robert Yarchoan	86
4	Phosphodiesterase-4 Inhibition Combined with Isoniazid Treatment of Rabbits with Pulmonary Tuberculosis Reduces Macrophage Activation and Lung Pathology 2011 ·American Journal Of Pathology ·Selvakumar Subbian,Liana Tsenova,Paul E. O’Brien,Guibin Yang,Mi-Sun Koo,Blas Peixoto,Dorothy Fallows,Jerome B. Zeldis,George W. Muller,Gilla Kaplan	68
5	Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response 2010 ·Cancer ·Asher Chanan‐Khan,Kena C. Miller,David Lawrence,Swaminathan P. Iyer,Austin Miller,(unknown),Myron S. Czuczman,Paul K. Wallace,Jerome B. Zeldis,Kelvin H. Lee	66
6	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma 2009 ·European Journal Of Haematology ·Edward A. Stadtmauer,Donna M. Weber,Rubén Niesvizky,Andrew Belch,(unknown),Jesús F. San Miguel,Thierry Façon,Marta Olesnyckyj,Zhinuan Yu,Jerome B. Zeldis,Robert Knight,Meletios Α. Dimopoulos	82
7	Efficacy of Dexmethylphenidate for the Treatment of Fatigue After Cancer Chemotherapy: A Randomized Clinical Trial 2009 ·Journal of Pain and Symptom Management ·Elyse E. Lower,Stewart B. Fleishman,(unknown),Jerome B. Zeldis,Herbert Faleck,Zhinuan Yu,Donald C. Manning	137
8	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure 2008 ·Blood ·Michael Wang,Meletios Α. Dimopoulos,Christine Chen,María Teresa Cibeira,Michel Attal,Andrew Spencer,S. Vincent Rajkumar,Zhinuan Yu,Marta Olesnyckyj,Jerome B. Zeldis,Robert Knight,Donna M. Weber	135
9	Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma 2008 ·Journal of Clinical Oncology ·Peter H. Wiernik,Izidore S. Lossos,Joseph M. Tuscano,Glen R. Justice,Julie M. Vose,Craig E. Cole,Wwt Lam,Kyle McBride,Kenton Wride,Dennis Pietronigro,Kenichi Takeshita,Annette Ervin‐Haynes,Jerome B. Zeldis,Thomas M. Habermann	300
10	Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy 2006 ·Annals of Oncology ·Rachid Baz,Esteban Walker,Mohamed A. Karam,Toni K. Choueiri,(unknown),(unknown),Janice Reed,Beth Faiman,(unknown),C. Brand,Gordan Srkalović,S Andresen,Robert Knight,Jerome B. Zeldis,Mohamed Hussein	116
11	Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletionbreakdown → 2006 ·New England Journal of Medicine ·Alan F. List,Gordon W. Dewald,John M. Bennett,Aristoteles Giagounidis,Azra Raza,Eric J. Feldman,Bayard L. Powell,Peter L. Greenberg,Deborah A. Thomas,Richard M. Stone,Craig B. Reeder,Kenton Wride,John Patin,M. Schmidt,Jerome B. Zeldis,Robert Knight	893
12	Thalidomide in the treatment of patients with hepatocellular carcinoma 2005 ·Cancer ·Yehuda Z. Patt,Manal M. Hassan,Richard D. Lozano,Ajay K. Nooka,(unknown),Jerome B. Zeldis,James L. Abbruzzese,Thomas D. Brown	75
13	ADouble-Blind, Placebo-Controlled Withdrawal Trial of Dexmethylphenidate Hydrochloride in Children with Attention Deficit Hyperactivity Disorder 2004 ·Journal of Child and Adolescent Psychopharmacology ·L. Eugene Arnold,Ronald L. Lindsay,C. Keith Conners,Sharon B. Wigal,(unknown),Diane E. Johnson,Scott A. West,R. Bart Sangal,Timothy P. Bohan,Jerome B. Zeldis	46
14	Comparative Pharmacodynamics and Plasma Concentrations of d-threo-Methylphenidate Hydrochloride After Single Doses of d-threo-Methylphenidate Hydrochloride and d,l-threo-Methylphenidate Hydrochloride in a Double-Blind, Placebo-Controlled, Crossover Laboratory School Study in Children With Attention-Deficit/Hyperactivity Disorder 2004 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Declan Quinn,Sharon B. Wigal,James M. Swanson,(unknown),(unknown),(unknown),Mark Roffman,Jerome B. Zeldis,Thomas B. Cooper	64
15	Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure 2002 ·Journal of Cardiac Failure ·(unknown),Ziad Dibbs,Feng Wang,George W. Muller,Jerome B. Zeldis,Douglas L. Mann,Biykem Bozkurt	22
16	Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: Report of a double-blind multicenter study 1992 ·Clinical Therapeutics ·John W. Bloom,(unknown),DORIS A. CHERNIK,Arnold B. Davidson,(unknown),(unknown),Paul A. Moore,Jane Siegel,Myron R. Tucker,(unknown),Jerome B. Zeldis	11
17	Chronic Hepatitis B Virus Infection in An Anti–Hbc-Nonreactive Blood Donor: Variant Virus or Defective Immune Response? 1992 ·Hepatology ·(unknown),Teresa Paglieroni,Paul V. Holland,Jerome B. Zeldis	28
18	In Vitro Hepatitis B virus suppression of erythropoiesis is dependent on the multiplicity of infection and is reversible with anti-HBs antibodies 1988 ·Hepatology ·Jerome B. Zeldis,Francis A. Farraye,Howard Steinberg	16
19	Primary hepatocellular carcinoma following nonspecific non-B hepatitis with tumor DNA negative for HBV DNA 1987 ·Digestive Diseases and Sciences ·(unknown),David L. Gang,Jerome B. Zeldis	13
20	The Harvey Lectures: Series 69, 1973-1974. 1976 ·The Yale Journal of Biology and Medicine ·Jerome B. Zeldis	13

About Jerome B. Zeldis

Jerome B. Zeldis is a scholar working on Hematology, Genetics and Hepatology, having authored 202 papers that have together received 15.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (103 papers), Cancer Treatment and Pharmacology (48 papers) and Chronic Lymphocytic Leukemia Research (32 papers). The work is most often cited by research in Hematology (10.1k citations), Genetics (3.4k citations) and Oncology (5.5k citations). Jerome B. Zeldis has collaborated with scholars based in United States, Greece and Canada. Frequent co-authors include Robert Knight, Zhinuan Yu, Marta Olesnyckyj, David S. Siegel, Bart Barlogie, Elias Anaissie, John Patin, Raman Desikan, Dan Ayers and Nikhil C. Munshi. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact